Biological Safety Testing Market Size, Share, Growth Analysis, By Application(Pharmaceutical & Biologics, Cellular & Gene Therapy, Blood & Blood Based Therapy, Other Applications), By Test(Sterility Tests, Bioburden Tests, Endotoxin Tests, Other Tests), By Region - Industry Forecast 2024-2031

Biological Safety Testing Market size was valued at USD 3.73 billion in 2021 and is poised to grow from USD 4.19 billion in 2023 to USD 10.77 billion by 2031, at a CAGR of 12.5% during the forecast period (2024-2031).

The global biological safety testing market is experiencing significant growth due to various factors such as increasing research and development activities in the pharmaceutical and biotechnology sectors, rising prevalence of infectious diseases, and growing awareness about the importance of quality control in the healthcare industry.

Biological safety testing involves the evaluation of biological products, such as vaccines, blood products, and cell-based therapies, to ensure their safety and efficacy before they are released for commercial use. The market is driven by the stringent regulatory requirements for the approval of biological products, which necessitate comprehensive safety testing to minimize the risk of adverse events.

Additionally, the increasing demand for advanced testing methods, such as nucleic acid amplification and sequencing techniques, is contributing to the market growth. These methods offer enhanced sensitivity and specificity in detecting potential contaminants in biological products, thereby improving patient safety.

Moreover, the growing adoption of in vitro testing methods, such as cell-based assays and immunoassays, is further propelling market expansion. These methods provide quicker results, reduce the need for animal testing, and offer cost-efficiency, driving their preference among researchers and manufacturers.

US Biological Safety Testing Market is poised to grow at a sustainable CAGR for the next forecast year.